Form 4: Aytu BioPharma Executive Greg Pyszczymuka Reports Stock Transactions
SEC Form 4 Filing
Chief Commercial Officer Greg Pyszczymuka reports the vesting of restricted stock units into Aytu BioPharma common shares.
Summary
- On March 31, 2025, Greg Pyszczymuka, Chief Commercial Officer of Aytu BioPharma, reported a transaction involving restricted stock units (RSUs).
- 209 common shares were acquired through the vesting of RSUs.
- Following the transaction, Pyszczymuka directly owns 23,602 common shares.
- The RSUs were granted on March 31, 2022, and vest quarterly, beginning March 31, 2023, and ending March 31, 2025.
Sentiment
Score: 5
Explanation: This is a routine regulatory filing related to stock transactions by a company insider. It doesn't inherently indicate positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This filing indicates the vesting of previously granted equity compensation.
Stakeholder Impact
- The vesting of RSUs may have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/31/2022 | Date the Restricted Stock Units (RSUs) were granted. |
| 03/31/2023 | Start date for quarterly vesting of RSUs. |
| 03/31/2025 | Date of the reported transaction (vesting of RSUs) and end date for quarterly vesting of RSUs. |
Keywords
Aytu BioPharma, Greg Pyszczymuka, Form 4, Stock Transaction, Restricted Stock Units, Common Shares, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.